Jim Sevey, a veteran of the biomaterial space, has just been appointed Senior Nanotechnology Specialist at Titan Spine, LLC. Sevey will lead the educational initiatives to further demonstrate and communicate the scientific evidence supporting the advantages of Titan Spine’s nanoLOCK surface technology.
Titan Spine President Kevin Gemas commented in the July 22, 2015 news release, “As our body of science continues to grow, we identified the need to bring onboard someone of Jim’s caliber to educate the spinal surgeon community and our sales force on the science and associated benefits of our current and nanoLOCK proprietary surface technologies. With more than 22 years of experience with medical devices and biomaterials, Jim is the right person to lead these efforts. One of Jim’s initial tasks will be to clearly differentiate the science of our nanotechnology platform from those that claim to have nanotechnology but have not been cleared by the FDA to do so. We are proud to add Jim to our ever-growing scientific team.”
According to the news release, “Before joining Titan Spine, Sevey held several positions at Synthes/DePuy Biomaterials, including most recently, Manager, Biomaterials Technical Specialist. In this role, he generated multidivisional sales of osteobiologic product lines by providing clinical and technical consulting, training, and education for surgeons, residents, operating room personnel, and sales consultants. Prior to Synthes/DePuy Biomaterials, Sevey was part of the founding team of Skeletal Kinetics, LLC, (Cupertino, CA) as Director of Marketing. Sevey holds a Bachelor of Science in Health Science from St. Mary’s College of California (Moraga, CA).”
Asked about how he will proceed in this new role, Sevey told OTW, “I am in a very unique and fortunate position joining Titan at this time, because much of the heavy lifting has already been done by the entire Titan Team. My initial focus will be boiling down the multiple peer-reviewed journal articles in order to deliver a concise scientific message and educational program on our current surface as well as our pending proprietary FDA cleared nanoLOCK surface technology. This truly is a unique opportunity because Titan Spine has always focused on the cellular science of bone healing and how it can benefit patients, rather than how a product can benefit investors. I firmly believe that if you focus on the patient and deliver a viable solution, which in this case is bone healing and fusion via the nanoLOCK surface, then the revenue will always follow.”
“My goals for the first year will mainly involve the development and delivery of the nanoLOCK educational program across a wide range of audiences of the spinal community utilizing our extensive group of key opinion leaders. I will also concentrate on refining and expanding the message as we obtain even more preclinical science and patient outcome clinical data. Evidence based medicine is here to stay, and the fact that Titan Spine has taken a very methodical and scientific approach to the design and development of the nanoLOCK surface, I believe we are very well positioned to continue our market share momentum. This will require a shift in focus from simply a spacer, which in some cases impedes fusions to a discussion on nanotechnology and how we can leverage the normal cellular processes to influence bone healing.”
